Does Highmark Cover Prolia?

What Is Prolia and Why Does Coverage Classification Matter?

Prolia is a RANK ligand inhibitor that reduces osteoclast activity, slowing bone resorption. The FDA approved denosumab (brand: Prolia) in June 2010 for postmenopausal women with osteoporosis at high fracture risk, and the labeling has since been expanded to include men with osteoporosis, patients on glucocorticoid therapy for at least six months, and patients experiencing bone loss from androgen deprivation therapy or aromatase inhibitor therapy [1].

How your plan classifies Prolia determines your out-of-pocket cost more than any other single factor.

Medical Benefit vs. Pharmacy Benefit

Because Prolia is administered by a healthcare professional in an office or infusion setting every six months, Highmark typically processes it as a medical benefit rather than a retail pharmacy benefit. Under a medical benefit structure, the drug's cost is included in the office visit or outpatient claim. Your cost-sharing is usually a percentage coinsurance (often 20%) of the plan-allowed amount, not a flat copay.

Occasionally, Highmark specialty pharmacy plans carve Prolia out to the pharmacy benefit. Under that arrangement, the drug ships to the prescribing office through a specialty distributor and your cost-sharing is determined by the specialty tier copay listed in your Summary of Benefits and Coverage (SBC).

Calling the Member Services number on the back of your Highmark card and asking specifically "Is Prolia covered under my medical benefit or pharmacy benefit?" is the fastest way to get a clear answer before your first injection.

FDA-Approved Indications That Highmark Recognizes

Highmark's clinical coverage policies align closely with the FDA label. The plan generally authorizes Prolia for:

• Postmenopausal osteoporosis with a T-score of -2.5 or lower, or a documented fragility fracture
• Osteoporosis in men at high fracture risk (T-score -2.5 or lower)
• Glucocorticoid-induced osteoporosis in adults at high fracture risk who are taking the equivalent of 7.5 mg/day or more of prednisone for six months or longer
• Bone loss associated with androgen deprivation therapy in men with non-metastatic prostate cancer
• Bone loss associated with aromatase inhibitor therapy in women with breast cancer

Off-label use is not covered without a formal medical necessity exception, which requires documented peer-reviewed literature and physician attestation.

Prior Authorization Requirements for Prolia on Highmark Plans

Prior authorization (PA) is standard for Prolia across virtually every Highmark product line. The PA process is the single biggest administrative hurdle most patients and prescribers encounter.

What Clinical Information Is Required

To submit a successful PA, your prescribing physician typically needs to supply:

1. A recent DEXA scan result showing T-score at or below -2.5, or documentation of a low-trauma (fragility) fracture
2. The specific FDA-approved indication being requested
3. Documentation of step therapy completion (see below)
4. A list of current medications and relevant comorbidities
5. Height, weight, and serum calcium level (hypocalcemia is a contraindication)

The American Association of Clinical Endocrinology (AACE) 2020 Clinical Practice Guidelines note that "patients with very high fracture risk may be candidates for anabolic therapy or denosumab as first-line treatment," which can support a step-therapy bypass request when your physician can document very high fracture risk using validated tools like FRAX [2].

Step Therapy and How to Request an Exception

Highmark's most common PA denial reason for Prolia is failure to document an adequate bisphosphonate trial. The plan typically requires:

• At least three to six months of alendronate (Fosamax) 70 mg weekly, risedronate (Actonel) 35 mg weekly, or an equivalent oral bisphosphonate
• Documented intolerance, contraindication, or therapeutic failure

If a patient cannot tolerate oral bisphosphonates due to esophageal disease, low eGFR (typically below 30-35 mL/min/1.73m²), or documented upper gastrointestinal adverse effects, Highmark's PA form includes a field for contraindication exceptions. Attach the relevant office notes, specialist letters, or lab values.

Timeline and Appeals

Highmark is required by Pennsylvania and other state insurance regulations, as well as federal rules under the ACA, to process standard PA requests within 15 calendar days and urgent PA requests within 72 hours. If the PA is denied, you have the right to an internal appeal and, in most states, an external independent review. A 2021 analysis published in JAMA Internal Medicine found that patients who appealed specialty drug denials won reversal in approximately 39-45% of cases, which underscores that a denial is not necessarily final [3].

Highmark Medicare Advantage and Prolia Coverage

Highmark offers several Medicare Advantage (MA) products in Pennsylvania, West Virginia, and Delaware. Prolia coverage under MA plans follows a different set of rules than commercial coverage because Medicare Part B governs injectable drugs administered in physician offices.

Part B vs. Part D for Denosumab

Under original Medicare and most Highmark Medicare Advantage plans, Prolia administered in a physician's office bills under Part B with a J-code (J0897 for denosumab 1 mg, billed in 60 units per injection). This means the drug is subject to the Part B deductible ($257 in 2025) and standard 20% coinsurance, or the MA plan's equivalent cost-sharing.

If your Highmark MA plan has reduced Part B coinsurance for certain drug categories, you may pay less than the standard 20%. Check your plan's Evidence of Coverage (EOC) document under "Part B drugs" or "covered injections" for the exact cost-sharing tier.

Highmark Medicare Advantage Prior Authorization for Prolia

Even within Medicare Advantage, Highmark applies PA criteria consistent with Medicare's national and local coverage determinations (LCDs). The relevant LCD for osteoporosis drug coverage in Highmark's service area is maintained by Novitas Solutions (MAC for Jurisdiction L). The Novitas LCD for bone density studies (L34856) and related drug coverage policies require documented clinical necessity [4].

Highmark's MA PA submission should include the same DEXA and clinical documentation described above. The plan cannot impose more restrictive criteria than original Medicare allows, per CMS rules, but it can add prior authorization as an administrative step.

Cost of Prolia With Highmark Coverage

Prolia's average wholesale price (AWP) runs approximately $1,400-$1,500 per 60 mg/mL prefilled syringe. With active Highmark coverage, your actual cost depends on your specific plan design.

Commercial Plan Cost-Sharing Examples

• HMO or PPO in-network, medical benefit: You pay your plan's coinsurance percentage (often 20-30% after deductible) of the plan-allowed rate, which is typically negotiated well below AWP.
• High-deductible health plan (HDHP): You pay 100% of the negotiated rate until you meet your deductible, then coinsurance applies. For Prolia injections, this means the first injection of the calendar year may be fully out-of-pocket if your deductible has not been met.
• Specialty tier pharmacy benefit: Flat copays of $150-$400 per fill are common on Highmark specialty tiers, though this structure is less frequently applied to Prolia than to oral specialty drugs.

Reducing Your Out-of-Pocket Cost

Amgen's Prolia Assist program offers enrolled commercially insured patients a copay card that may reduce their cost to as low as $0 per dose, subject to eligibility restrictions. The program excludes patients whose primary insurance is a federal or state government program (Medicare, Medicaid, TRICARE). Commercial Highmark members can enroll at Amgen's patient support line.

Patients on Medicare Advantage with financial hardship may qualify for Amgen's patient assistance program, which can provide Prolia at no cost. Income and household size thresholds apply.

Clinical Evidence Supporting Prolia Coverage Decisions

Understanding the trial data behind Prolia helps contextualize why Highmark and other payers require specific clinical criteria. Coverage policies are built, at least in part, on the demonstrated efficacy and safety profile from registration trials.

The FREEDOM Trial

The FREEDOM trial (N=7,868) is the key phase 3 study that formed the basis of FDA approval. Postmenopausal women with a lumbar spine T-score between -2.5 and -4.0 were randomized to denosumab 60 mg subcutaneously every six months or placebo over 36 months. Denosumab reduced the risk of new vertebral fractures by 68% (7.2% placebo vs. 2.3% denosumab; relative risk 0.32; 95% CI 0.26-0.41; P<0.001) [5]. Hip fracture risk was reduced by 40% (1.2% vs. 0.7%; P = 0.04).

These numbers matter when writing a PA letter. Citing FREEDOM data to document why a high-fracture-risk patient qualifies for Prolia over a bisphosphonate gives the PA reviewer a clinical anchor.

The FREEDOM Extension

The FREEDOM Extension followed patients for up to 10 years of continuous denosumab therapy. Bone mineral density continued to increase through year 10, with lumbar spine BMD gains of 21.7% from baseline [6]. This long-term data is particularly relevant for Highmark PA renewals, because some plans require re-authorization every 12 or 24 months.

Discontinuation Risk: A Critical Clinical Point

One aspect of Prolia coverage that payers and prescribers both should understand: stopping denosumab abruptly causes rapid bone loss and may trigger multiple vertebral fractures. A 2019 study published in the Journal of Bone and Mineral Research reported that 14 of 60 patients who discontinued denosumab experienced multiple vertebral fractures within 12-18 months of stopping [7]. This is not a theoretical concern.

The HealthRX clinical team recommends that prescribers include a "discontinuation plan" in the PA documentation for every Prolia authorization. If Highmark later denies a renewal, having a documented transition strategy to a bisphosphonate or anabolic agent prevents dangerous gaps in bone protection. The 2022 AACE/ACE Postmenopausal Osteoporosis guidelines explicitly state that "if denosumab is discontinued, antiresorptive therapy should be started to maintain BMD gains and mitigate rebound fracture risk" [8].

Alternatives Highmark May Require Before Approving Prolia

If Highmark denies Prolia due to step therapy, the following agents are the most commonly required first-line options.

Oral Bisphosphonates

Alendronate (generic Fosamax) 70 mg once weekly is by far the most frequently required step-therapy drug. It is available as a generic for under $10 per month at most pharmacies and has 30+ years of fracture reduction data. The FIT trial (N=2,027) showed alendronate reduced vertebral fracture risk by 47% over three years in women with low BMD and prior vertebral fracture [9].

Risedronate (Actonel or generic) 35 mg weekly is an alternative. Ibandronate (Boniva) 150 mg monthly is a third option, though it has less non-vertebral fracture data.

Intravenous Zoledronic Acid

Zoledronic acid (Reclast) 5 mg IV once yearly is often accepted as a step-therapy alternative when oral bisphosphonates are contraindicated. The HORIZON-PFT trial (N=7,765) showed zoledronic acid reduced hip fracture risk by 41% and vertebral fracture risk by 70% over 36 months [10]. For patients with severe GI intolerance or esophageal disease, documenting zoledronic acid as the appropriate alternative can allow a Highmark PA to bypass the oral bisphosphonate requirement.

Raloxifene

Raloxifene (Evista) 60 mg daily is occasionally listed as a step-therapy option on older Highmark formularies. The MORE trial (N=7,705) showed a 30-50% reduction in vertebral fracture risk but no significant hip fracture benefit [11]. Raloxifene is rarely the preferred first-line option for patients with high hip fracture risk, and a prescriber can document this limitation to support a Prolia exception.

How to Verify Your Specific Highmark Plan Coverage for Prolia

Coverage policies differ across Highmark's product lines: Highmark Blue Cross Blue Shield (Pennsylvania), Highmark Blue Shield, Highmark BCBS West Virginia, Highmark BCBS Western New York, and Highmark Blue Cross Blue Shield Delaware all maintain distinct formularies and PA policies.

Step-by-Step Verification Process

1. Locate your member ID card and identify your specific plan name and group number.
2. Call Member Services (the number is on the back of your card) and ask: "Is Prolia covered under my plan? Is it a medical or pharmacy benefit? Does it require prior authorization?"
3. Request a copy of the relevant coverage policy (often called a Clinical Coverage Policy or Medical Policy bulletin). Highmark publishes many of these on its provider portal.
4. Have your prescriber submit a PA request using Highmark's online portal or the paper PA form for specialty biologics. Include DEXA results, fracture history, and any step-therapy documentation.
5. Track the PA timeline. Standard decisions must come within 15 days; urgent decisions within 72 hours. Follow up in writing if you have not received a response.
6. Appeal if denied. Request the specific denial reason in writing, respond to each criterion with clinical documentation, and escalate to external review if the internal appeal fails.

Using the Highmark Provider Portal

Prescribers can submit PA requests through NaviNet or the Highmark provider portal. Most practices use electronic PA submission through their EHR or a clearinghouse. Response times through electronic submission are typically faster than paper submission.

Special Situations Affecting Highmark Prolia Coverage

Glucocorticoid-Induced Osteoporosis

Patients taking prednisone 7.5 mg/day or equivalent for six months or more qualify for Prolia under a separate indication. The American College of Rheumatology (ACR) 2022 Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis conditionally recommends denosumab for high-fracture-risk patients on long-term glucocorticoids who cannot use oral bisphosphonates [12]. Citing the ACR guideline in the PA letter strengthens the case considerably.

Cancer-Related Bone Loss

For patients receiving androgen deprivation therapy (ADT) for prostate cancer or aromatase inhibitors (AIs) for breast cancer, Prolia's coverage pathway may run through the oncology benefit rather than the standard osteoporosis benefit. Confirm with your Highmark plan whether your oncologist or your primary care physician should submit the PA.

Renal Impairment

Bisphosphonates are generally contraindicated when eGFR falls below 30-35 mL/min/1.73m². Prolia does not require dose adjustment for renal impairment and is often the preferred agent in chronic kidney disease (CKD) stages 3b-4. Documenting an eGFR below 35 mL/min/1.73m² is one of the strongest contraindication arguments for bypassing bisphosphonate step therapy in a Highmark PA.